Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3449]

Rituximab-based chemotherapy achieves strong outcomes without routine...

Dr Konstantinos Christofyllakis - Saarland University, Saarbrücken, Germany

Rituximab-based chemotherapy achieves strong outcomes without routine radiotherapy in stage I extranodal large B-cell lymphoma ( Dr Konstantinos Christofyllakis - Saarland University, Saarbrücken, Germany )

Encorafenib plus FOLFIRI improves response rates in BRAF-mutant metastatic...

Prof Scott Kopetz - MD Anderson Cancer Center, Housten, USA

Encorafenib plus FOLFIRI improves response rates in BRAF-mutant metastatic colorectal cancer ( Prof Scott Kopetz - MD Anderson Cancer Center, Housten, USA )

Durvalumab plus chemotherapy improves outcomes and urine tumour DNA predicts...

Dr Michiel van der Heijden - Netherlands Cancer Institute, Amsterdam...

Durvalumab plus chemotherapy improves outcomes and urine tumour DNA predicts response in muscle-invasive bladder cancer ( Dr Michiel van der Heijden - Netherlands Cancer Institute, Amsterdam, Netherlands )

Zolbetuximab plus nivolumab and chemotherapy shows promising responses in...

Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan

Zolbetuximab plus nivolumab and chemotherapy shows promising responses in CLDN18.2-positive metastatic gastric cancer ( Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan )

EAU 2026: Updates in NMIBC

Dr Francesco Soria, Prof Jonathan Aning, Dr Antoni Vilaseca and Prof Alexandra...

EAU 2026: Updates in NMIBC ( Dr Francesco Soria, Prof Jonathan Aning, Dr Antoni Vilaseca and Prof Alexandra Masson-Lecomte )

Adding LAG-3 or TIGIT immunotherapy to enfortumab vedotin plus pembrolizumab...

Dr Michiel van der Heijden - Netherlands Cancer Institute, Amsterdam...

Adding LAG-3 or TIGIT immunotherapy to enfortumab vedotin plus pembrolizumab does not improve outcomes in advanced UC ( Dr Michiel van der Heijden - Netherlands Cancer Institute, Amsterdam, Netherlands )

Pembrolizumab alone achieves bladder preservation and ctDNA predicts outcomes...

Dr Jonathan Anker - Mount Sinai Hospital, New York, USA

Pembrolizumab alone achieves bladder preservation and ctDNA predicts outcomes in muscle-invasive bladder cancer ( Dr Jonathan Anker - Mount Sinai Hospital, New York, USA )

Cabozantinib plus nivolumab and ipilimumab improves response in low GDS mRCC...

Dr Nicholas Salgia - Roswell Park Comprehensive Cancer Center, Buffalo, USA

Cabozantinib plus nivolumab and ipilimumab improves response in low GDS mRCC while high GDS predicts worse survival ( Dr Nicholas Salgia - Roswell Park Comprehensive Cancer Center, Buffalo, USA )

Enzalutamide plus radium-223 extends survival in bone metastatic prostate cancer

Dr Enrique Gallardo - Parc Taulí University Hospital, Sabadell, Spain

Enzalutamide plus radium-223 extends survival in bone metastatic prostate cancer ( Dr Enrique Gallardo - Parc Taulí University Hospital, Sabadell, Spain )

AMVAC plus nivolumab in muscle-invasive bladder cancer preserves bladder and...

Dr Pooja Ghatalia - Fox Chase Cancer Center, Pennsylvania, USA

AMVAC plus nivolumab in muscle-invasive bladder cancer preserves bladder and predicts metastatic control with ctDNA ( Dr Pooja Ghatalia - Fox Chase Cancer Center, Pennsylvania, USA )

Cabozantinib plus nivolumab and ipilimumab shows promising brain metastasis...

Dr Jianbo Wang - MD Anderson Cancer Center, Houston, USA

Cabozantinib plus nivolumab and ipilimumab shows promising brain metastasis control in advanced kidney cancer ( Dr Jianbo Wang - MD Anderson Cancer Center, Houston, USA )

Belzutifan plus palbociclib shows modest activity with manageable safety in...

Dr David McDermott - Beth Israel Deaconess Medical Center, Boston, USA

Belzutifan plus palbociclib shows modest activity with manageable safety in heavily pretreated kidney cancer ( Dr David McDermott - Beth Israel Deaconess Medical Center, Boston, USA )

More from ecancer